Manatuck Hill Partners LLC Invests $544,000 in Boston Scientific Corporation $BSX

Posted by Stanley Muller on Aug 26th, 2026

Boston Scientific logo Manatuck Hill Partners LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 12,738 shares of the medical equipment provider’s stock, valued at approximately $544,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific in the 1st quarter worth approximately $28,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

BSX stock opened at $49.86 on Wednesday. The firm has a 50-day moving average of $46.44 and a two-hundred day moving average of $57.14. The firm has a market capitalization of $72.26 billion, a PE ratio of 20.19, a P/E/G ratio of 1.07 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have weighed in on BSX shares. Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Argus reissued a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Truist Financial decreased their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Read Our Latest Stock Analysis on Boston Scientific

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.